Who are MANGAFODIPIR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GADOFOSVESET, Primovist, Optimark, Omniscan, Prohance, MultiHance 0.1 mmol/kg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mangafodipir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

MANGAFODIPIR — Competitive Intelligence Brief

MANGAFODIPIR (MANGAFODIPIR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Paramagnetic Contrast Agent. Area: Gastroenterology.

marketed Paramagnetic Contrast Agent Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

MANGAFODIPIR (MANGAFODIPIR).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MANGAFODIPIR TARGET	MANGAFODIPIR		marketed	Paramagnetic Contrast Agent		1997-01-01
GADOFOSVESET	GADOFOSVESET	Lantheus Medcl	marketed	Paramagnetic Contrast Agent		2008-01-01
Primovist	GADOXETIC ACID		marketed	Paramagnetic Contrast Agent		2008-01-01
Optimark	GADOVERSETAMIDE	Liebel-Flarsheim	marketed	Paramagnetic Contrast Agent		1999-01-01
Omniscan	GADODIAMIDE	GE HealthCare	marketed	Paramagnetic Contrast Agent [EPC]		1993-01-01
Prohance	GADOTERIDOL	Bracco	marketed	Paramagnetic Contrast Agent		1992-01-01
MultiHance 0.1 mmol/kg	MultiHance 0.1 mmol/kg	Bracco Diagnostics, Inc	marketed	Paramagnetic contrast agent; gadolinium-based MRI contrast medium	Water protons in tissue; blood-brain barrier; vascular endothelium

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Paramagnetic Contrast Agent class)

· 3 drugs in this class
Bracco · 1 drug in this class
Lantheus Medcl · 1 drug in this class
Liebel-Flarsheim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MANGAFODIPIR — Competitive Intelligence Brief. https://druglandscape.com/ci/mangafodipir. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab